Rhizomatic Strategizing in Digital Transformation: A Clinical Field Study

Magnusson, Johan; Khisro, Jwan; Lindroth, Tomas; Nilsson, Andréas; Norling, Kristian

doi:10.24251/hicss.2022.777

Cited by 4 publications

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Adapting agile development practices for hyper-agile environments: lessons learned from a COVID-19 emergency response research project

et al. 2022

View full text Add to dashboard Cite

Agile development is known for efficient software development practices that enable teams to quickly develop software to cope with changing requirements. Although there is evidence that agile practices are helpful in such environments, the literature does not inform us as to whether agile practices can also be beneficial in hyper-agile environments. Such environments are characterized by an extremely fast pace of change with fluid requirements. COVID-19 vaccine distribution is one such problem that governments have had to deal with. To solve this problem, governments need to come up with robust responses by formulating teams that have the capability to provide software solutions enabling information visibility into the vaccine distribution process. Such emergent teams need to quickly understand the distribution process, oftentimes define the process itself because it might be non-existent, and build software systems to solve the problem in a matter of days. Not much is known about how systems can be developed at such a fast pace. We adopt a clinical research methodology and employ agile software development practices to develop such a mission-critical system. In the process of building the system, we learn important lessons that can be used to adapt and extend agile methodologies to be used in hyper-agile development environments. We offer these lessons as important first steps to understanding the best practices needed to develop software systems that have the capability to provide visibility into the unprecedented health challenge of distribution of life-saving COVID-19 vaccine.

show abstract